LSNE Successfully Completes MHRA Inspection

News
Article

Lyophilization Services of New England (LSNE) received a Certificate of GMP Compliance for its New Hampshire facility.

The CMO Lyophilization Services of New England (LSNE) reports that its manufacturing facility in Bedford, New Hampshire has received a Certificate of GMP Compliance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to manufacture aseptic lyophilized drug products for use in the European Union. LSNE underwent an initial inspection in May 2013 and was found to be compliant with EU GMP with no critical or major findings. After completion of an audit and registration, LSNE was issued a Certificate of GMP Compliance of a Pharmaceutical Manufacturer from the MHRA. The Bedford facility is now certified for the manufacture of sterile lyophilized drug products to be marketed in the EU.

Source: LSNE

Recent Videos
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Related Content